BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...testing to treat spasticity in multiple sclerosis in November 2015, followed in 2016 by 68Ga- OPS202...
BioCentury | Jun 29, 2015
Company News

OctreoPharm, Ipsen deal

...and up to about EUR20 million ($22.6 million) in milestones. Ipsen will gain SOMscan ( OPS202...
...SOMther ( OPS201 ), a radionuclide therapy labeled with yttrium-90 or lutetium-177 that antagonizes SSTR2. SOMscan...
BioCentury | Oct 27, 2014
Clinical News

SOMscan regulatory update

...FDA granted Orphan Drug designation to diagnostic agent OPS202 from OctreoPharm for managing neuroendocrine tumors. OPS202...
...antagonizes somatostatin receptor 2 (SSTR2) . OctreoPharm Sciences GmbH , Berlin, Germany Product: SOMscan , OPS202...
BioCentury | Feb 3, 2014
Clinical News

SOMscan regulatory update

...OctreoPharm said the European Commission granted Orphan Drug designation to OPS202 as a diagnostic agent for...
...gallium-68-labeled radioactive agent for PET imaging that antagonizes somatostatin receptor 2 (SSTR2) . OctreoPharm said OPS202...
...a European Phase I trial "soon." OctreoPharm Sciences GmbH , Berlin, Germany Product: SOMscan , OPS202...
Items per page:
1 - 4 of 4